IMMP · ASX
Average $73.42 (+2194.5% upside)
The latest rating actions, newest first
| Firm | Date | Action | Rating |
|---|---|---|---|
| Maxim Group | Jun 17, 2026 | Upgrade | Hold → Buy |
| Citizens | Mar 13, 2026 | Downgrade | Market Outperform → Market Perform |
| Baird | Mar 13, 2026 | Downgrade | Outperform → Neutral |
| Citizens | Feb 23, 2026 | Initiates | Market Outperform |
| Citizens | Feb 17, 2026 | Initiates | Market Outperform |
Updated Aug 4, 2026
Immutep is well-positioned for success with their diversified product pipeline and strong leadership, making them a promising investment opportunity for the long-term. However, investors should be aware of potential risks related to stock market volatility and regulatory approval challenges. Overall, with expected positive results from their Phase 3 and Phase 2b trials, Immutep has the potential for significant growth in the future.
Immutep is highly reliant on the FDA's pace of evaluating new drugs and their willingness to approve them, making it risky and dependent on external factors. Their positioning as a complementary agent rather than a direct competitor could negatively impact market potential, and there is confusion among experts regarding the drug's mechanism. Additionally, the clinical trials for both NSCLC and HNSCC have small sample sizes, and the data should be interpreted with caution.
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.
